Incorporating novel agents in the management of elderly myeloma patients

Current Hematologic Malignancy Reports

Volumn 8, Issue 4, 2013, Pages 261-269

  Guglielmelli, Tommasina ^a   Palumbo, Antonio ^b  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Adverse events; Bortezomib; Dose reduction; Elderly patients; Lenalidomide; Multiple myeloma; Thalidomide

Indexed keywords

ANTIANEMIC AGENT; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DARATUZUMAB; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; IXAZOMIB CITRATE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PARABINOSTAT; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ADD ON THERAPY; ANEMIA; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER RECURRENCE; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CONSOLIDATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INFECTION; KIDNEY FAILURE; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REDUCED INTENSITY CONDITIONING; SENESCENCE; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MULTIPLE MYELOMA; RECURRENCE;

EID: 84890502599     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-013-0177-y     Document Type: Article

References (54)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046-60.
2. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335-48. This paper reports an interesting theory: myeloma is a heterogeneous disease characterized by different sub-clones that determine the disease course and the possible response to drugs.
3. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2013, in press.
4. Ludwig H, Avet-Loiseau H, Bladé J, et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist. 2012;17:592-606.
5. Lonial S, Miguel JF. Induction therapy for newly diagnosed multiple myeloma. J Natl Compr Canc Netw. 2013;11:19-28.
6. Palumbo A, Mina R. Part II: role of maintenance therapy in transplant-ineligible patients. J Natl Compr Canc Netw. 2013;11:43-9.
7. Howlade N, Noone A, Krapcho M, et al. Seer Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2012 [ http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 seer data submission, posted to the seer web site].
8. Beker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25-35.
9. Landgren Q, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23:1691-7.
10. Alavanja MC, Ross MK, Bonner MR. Increased cancer burden among pesticide applicators and others due to pesticide exposure. CA Cancer J Clin. 2013;63:120-42.
11. Greenberg AJ, Rajkumar SV, Vachon CM. Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood. 2012;119:5359-66.
12. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of European Myeloma Network (EMN). Blood. 2011;118:4519-29. An important and recent EMN report on frail patients.
13. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23:1716-30.
14. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104:3052-7.
15. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients. J Clin Oncol. 2010;28:800-7.
16. Straka C, Schafer-Eckart K, Bassermann F, et al. Prospective randomized trial of Len/Dex induction followed by tandem Mel 140 with autologous blood stem cell transplantation and Len maintenance versus continued therapy with Len/Dex in myeloma patients age 60-75 years: protocol-defined safety analysis after 100 patients. Abstract presented at the 54th American Society of Hematology conference. Atlanta, Georgia; December 8-11, 2012.
17. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006;367:825-31.
18. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112:107-14.
19. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209-18.
20. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28:3160-6.
21. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27:64-70.
22. Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116:1405-12.
23. Beksac M, Haznedar R, Firatli-Tuglular T, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011;86:16-22.
24. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118:1239-47. An interesting meta-analysis combining patient data from 6 randomized trials with MPT.
25. Palumbo A, Waage A, Hulin C, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013;98:87-94.
26. Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118:1231-8.
27. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-17.
28. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010;28:2259-66.
29. San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan- prednisone versus melphalan-prednisone in patients with previously untreated myeloma. J Clin Oncol. 2013;31:448-55. A recent update of the VISTA study confirming the benefit of VMP over MP.
30. Mateos MV, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11:934-41.
31. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28:5101-9.
32. Palumbo A, Bringhen S, Rossi D, et al. Overall survival benefit for bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in newly diagnosed multiple myeloma patients. Abstract presented at the 54th American Society of Hematology conference. Atlanta, Georgia; December 8-11, 2012. The study with the highest rate of CR. Median overall survival was not reached yet, and it may be quite high.
33. Falco P, Cavallo F, Larocca A, et al. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia. 2013;27:695-701.
34. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;336:1759-69. A recent study confirming the benefit of lenalidomide maintenance after MPR treatment.
35. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29-37.
36. Mateos MV, Oriol A, Martínez-López J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012;120:2581-8.
37. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745-53.
38. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431-40.
39. Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-98.
40. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007;137:429-35.
41. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123-32.
42. Weber DM, Chen C, Niesvisky R, et al. lenalidomide plus dexamethasone for relapsed myeloma in North America. N Engl J Med. 2007;357:2133-42.
43. Touzeau C, Blin N, Clavert A, et al. Efficacy of lenalidomide and dexamethasone in patients older than 75 years with relapsed multiple myeloma. Leuk Lymphoma. 2012;53:1318-20.
44. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892-901.
45. Guglielmelli T, Bringhen S, Rrodhe S. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. patients. Eur J Cancer. 2011;47:814-8.
46. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817-25. Recent protocol showing promising results with carfilzomib.
47. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012;119:5661-70. Recent protocol showing promising results with carfilzomib.
48. MA Dimopoulos, MD1, MQ Lacy, et al. Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. Abstract presented at the 54th American Society of Hematology conference. Atlanta, Georgia; December 8-11, 2012. Recent study confirming the benefit of salvage therapy with pomalidomide after lenalidomide and bortezomib.
49. Gay F, Palumbo A. Management of older patients with multiple myeloma. Blood Rev. 2011;25:65-73.
50. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144:895-903.
51. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-23.
52. Dimopoulos MA, Terpos E, Chana-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976-84.
53. Terpos E, Sezer O, Crocher PI, et al. The use of biphosphonates in multiple myeloma: recommendation of an expert panel on behalf of the International Myeloma Working Group. J Clin Oncol. 2009;20:1303-17.
54. Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98:980-7.